Deutsche Bank raised the firm’s price target on Eli Lilly to $695 from $535 and keeps a Hold rating on the shares. The analyst updated the company’s model post the Q4 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Foghorn Therapeutics says Lilly selects FHD-909 for clinical development
- Eli Lilly price target raised to $865 from $710 at BMO Capital
- Eli Lilly price target raised to $850 from $650 at Truist
- Amgen downgraded to Market Perform from Outperform at Leerink
- Eli Lilly price target raised to $825 from $700 at Wells Fargo